Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 16/20 | 0.98 |
| ▸ | PDE4B | Q07343 | 16/20 | 0.98 |
| ▸ | PDE4C | Q08493 | 16/20 | 0.98 |
| ▸ | PDE4D | Q08499 | 16/20 | 0.98 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.46 |
| ▸ | TUBB | P07437 | 1/20 | 0.46 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.46 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.46 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.46 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.46 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.46 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.46 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.46 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.46 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.46 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.46 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.46 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.46 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Awd-12-281 SCHEMBL29413256 | 0.99 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DTUBB4A | |
| Awd-12-281 SCHEMBL155120 | 0.99 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DTUBB4A | |
| Awd-12-281 SCHEMBL5638122 | 0.98 | PDE4A (0.98) | PDE4APDE4BPDE4CPDE4DTUBB4A | |
| SCHEMBL3101476 | 0.93 | PDE4A (0.89) | PDE4APDE4BPDE4CPDE4DTUBB4A | |
| SCHEMBL6255980 | 0.93 | PDE4A (0.89) | PDE4APDE4BPDE4CPDE4DTUBB4A | |
| SCHEMBL5637675 | 0.91 | PDE4A (0.85) | PDE4APDE4BPDE4CPDE4DTUBB4A | |
| SCHEMBL5637676 | 0.89 | PDE4A (0.82) | PDE4APDE4BPDE4CPDE4DTUBB4A | |
| SCHEMBL27554475 | 0.89 | PDE4A (0.81) | PDE4APDE4BPDE4CPDE4DTUBB4A | |
| SCHEMBL28618046 | 0.88 | PDE4A (0.80) | PDE4APDE4BPDE4CPDE4DTUBB4A | |
| SCHEMBL5636873 | 0.87 | PDE4A (0.78) | PDE4APDE4BPDE4CPDE4DPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7161009-B2 | Hydroxyindoles, their use as inhibitors of phosphodiesterase 4 and processes for their preparation | ELBION AG (DE) | 2007-01-09 | — | — | US | claimed |
| CN-1234705-C | Novel hydroxyindoles, their use as phosphodiesterase 4 inhibitors and process for their preparation | ELBION AG (DE) | 2006-01-04 | — | — | CN | claimed |
| US-20040220183-A1 | inhibiting tumor necrosis factor; respiratory system disorders; prevent neutrophil infiltration in lungs; skin disorders | HOFGEN NORBERT (DE) | 2004-11-04 | — | — | US | claimed |
| US-6545158-B2 | Such as N-(3,5-dichloropyridin-4-yl)-2-(1-(4-fluorobenzyl)-5-hydroxyindol-3-yl)-2 -oxoacetamide; for treatment of eosinophil-related disorders and chronic obstructive pulmonary disease | ARZNEIMITTELWERK DRESDEN GMBH (DE) | 2003-04-08 | — | — | US | claimed |
| CN-1307575-A | Novel hydroxyindoles, their use as phosphodiesterase 4 inhibitors and process for their preparation | DRESDEN ARZNEIMITTEL (DE) | 2001-08-08 | — | — | CN | claimed |
| CN-1321981-C | Hydroxyindoles, their use as phosphodiesterase 4 inhibitors and process for their preparation | ELBION AG (DE) | 2007-06-20 | — | — | CN | disclosed |
| CN-1234705-C | Novel hydroxyindoles, their use as phosphodiesterase 4 inhibitors and process for their preparation | ELBION AG (DE) | 2006-01-04 | — | — | CN | disclosed |
| CN-1699342-A | Novel hydroxyindoles, their use as phosphodiesterase 4 inhibitors and process for their preparation | ELBION AG (DE) | 2005-11-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220183-A1 | inhibiting tumor necrosis factor; respiratory system disorders; prevent neutrophil infiltration in lungs; skin disorders | MMP8, MPO, TNF | PDE4A 7/4885PDE4B 21/4885PDE4C 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.